Ascendis Pharma Announces Share Buyback After Product Revenue Surge
1 report, 1 independent
Updated Sep 20
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascendis Pharma announced that its Board had authorized buying back up to $400 million of its ordinary shares. The company reported Q2 results for the period ending June 30, showing product revenue reached €315 million, a 105% increase year over year. Yorvipath accounted for €252 million of that revenue, while the company also posted an operating profit of €220 million.
From insidermonkey.com
Why it matters
The company utilized its strong financial health, which includes €812 million in cash reserves as of June 30, to fund the buyback. This follows a period where the company had previously reported losses.
From insidermonkey.com
Who's involved
- Morgan StanleyAnnounced a buyback program and reported Q2 financial results